Project Name: Barts Nuclear Medicine Service Redesign

Project Summary:

This Collaborative Working Agreement (CWA) aims to recruit one FTE Nuclear Medicine Technologist to support the collaborative working (CW) partner with the co-ordination, management and treatment of patients in the nuclear medicine therapies service. 

The recruitment of the Nuclear Medicine Technologist is part of the Trust’s work to expand its nuclear medicine therapy service sustainably.

The expected outcomes of this CWP are: 

  • Improved patient outcomes and experience by reducing time between decision to treat and first treatment initiation
  • Increased number of patients able to access molecular radiotherapies  by providing additional capacity for treatment co-ordination, set-up and delivery
  • Improve staff experience within nuclear medicine department through improved co-ordination, educating ancillary staff and ward nurses in radiation protection and liaising with departmental technologists around staffing levels and resource requirements. 

The improved outcomes from the service expansion will enable a business case to be developed by the trust for permanent provision to ensure long term sustainability of the project.

Planned Milestones:

Duration of Project: 33 months, including 24 months clinical activity.

  • Recruitment to Nuclear Medicine Technologist role
  • Collection of baseline data, in line with Project Outcome Measures & Data Collection table, provide anonymised and aggregated data to Novartis
  • Collection & submission of clinical activity data in 3 monthly intervals until completion at 24 months, provide anonymised and aggregated data to Novartis
  • Project Review meeting at 3 monthly intervals until completion at 24 months to discuss project progress, provide anonymised and aggregated data to Novartis
  • Collection of staff satisfaction survey at baseline, midpoint and endpoint, provide anonymised and aggregated data to Novartis
  • Development of business case and analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary

Expected Benefits:

Patient benefits

  • Improved treatment information and access to a range of radionuclide therapies. 
  • Reduction in time to treatment from a decision to treat. 
  • Enhanced and more equitable experience for patients and their carers from North East London, reducing travel and improving access to locally available specialist. 
  • Enhanced clinical support for patients.

Organisation benefits

  • Improve overall quality of care and ensure greater equity of access to molecular radiotherapies for eligible patients. 
  • Reduction in waiting list times and improved molecular radiotherapy treatment capacity. 
  • Increased awareness of nuclear medicine therapy availability and treatment pathways. 
  • Maintaining standards for Centre of Excellence for Theranostics and developing standards for potential future NETs Centre of excellence application.

Novartis benefits

  • Improved understanding of the unmet needs of customers and patients
  • Increased access to Nuclear Medicine Therapies (which may include Novartis Therapies)

Start Date & Duration: CWP to last 33 months from February 2025. 
24 months of clinical activity.

FA-11360243 | February 2025